Unfortunately, the AZ trial is a mess. One way it was a mess is that the error bars on how much they prevent all illness (not just symptomatic illness) go all the way down to 1%.
That seems substantial, weird and important. Source?
https://clinicaltrials.gov/ct2/show/NCT04516746
"The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age [ Time Frame: 1 year ]
A binary response, whereby a participant is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs
≥ 15 days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case."
https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
"The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. "
So at the end of the day, the main question regarding the AZ/Oxford vaccine is whether a half-dose starter shot regimen, or longer time between doses can bring its efficacy more consistently up around 90%, which would make it only slightly less effective than the mRNA ones, or if it's efficacy is actually just lower.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
"To test for asymptomatic infections, participants in COV002 in the UK were asked to provide a weekly self-administered nose and throat swab for NAAT testing from 1 week after first vaccination using kits provided by the UK Department of Health and Social Care (DHSC)"
Moderna:
https://www.nih.gov/news-events/news-releases/phase-3-clinic... "Investigators will closely monitor participant safety. They will call participants after each vaccination to discuss any symptoms and will provide participants with a diary to record symptoms and a thermometer for temperature readings. If a participant is suspected to have COVID-19, the participant will be asked to provide a nasal swab for testing within 72 hours."
https://www.nejm.org/doi/10.1056/NEJMoa2035389 "although our trial showed that mRNA-1273 reduces the incidence of symptomatic SARS-CoV-2 infection, the data were not sufficient to assess asymptomatic infection, although our results from a preliminary exploratory analysis suggest that some degree of prevention may be afforded after the first dose"
Pfizer:
https://www.sciencemediacentre.org/expert-reaction-to-phase-... "The Pfizer study did not report studies of the impact of its vaccine on asymptomatic infection. The Oxford study reported that efficacy for “asymptomatic or symptoms unknown infection” based on weekly self-swabbing was 3·8% (−72·4 to 46·3%) following standard dose and 58·9% (95% CI 1·0 to 82·9) following low dose regimen."
https://www.nejm.org/doi/10.1056/NEJMoa2034577 "These data do not address whether vaccination prevents asymptomatic infection; a serologic end point that can detect a history of infection regardless of whether symptoms were present (SARS-CoV-2 N-binding antibody) will be reported later"
PS: Sorry, but it took a little while to dig up original sources to random news articles I'd read months earlier
I sometimes post something here and completely forget to look for replies. I'd hate to come back a week later to find out I'd been vilified for it.
Where did you get that from?
Because it was deleted I can't check if it was you or not. I had it open in a tab and it disappeared when I refreshed.
[1] https://twitter.com/chrislhayes/status/1355352505987854340